As a minimally invasive drug delivery platform, microneedles (MNs) overcome many drawbacks of the conventional transdermal drug delivery systems, therefore are favorable in biomedical applications. Microneedles with a combined burst and sustained release profile and maintained therapeutic molecular bioactivity could further broaden its applications as therapeutics. Here, we developed a double-network microneedles (DN MNs) based on gelatin methacrylate and acellular neural matrix (GelMA-ACNM). ACNM could function as an early drug release matrix, whereas the addition of GelMA facilitates sustained drug release. In particular, the double-network microneedles comprising GelMA-ACNM hydrogel has distinctive biological features in maintaining drug activity to meet the needs of application in treating different diseases. In this study, we prepared the double-network microneedles and evaluated its morphology, mechanical properties, drug release properties and biocompatibility, which shows great potential for delivery of therapeutic molecules that needs different release profiles in transdermal treatment.
Effective blood glucose management is an increasing demand worldwide. Traditional solutions separate glucose detection and insulin delivery, which is less efficient compared to emerging closed‐loop wearable systems controlled by continuous glucose monitors (CGMs). However, CGM‐controlled systems raise new safety risks, as false CGMs readings can cause insulin overdose, which results in hypoglycemia and fatal consequences. This work proposes a concept of a dual closed‐loop insulin delivery system (DuoLoop) to mitigate the risk issue of CGM‐controlled systems. The first closed‐loop is automated insulin delivery controlled by CGM. The second closed‐loop is the controlled release of glucose‐responsive insulin (GRI), whose release rate depends on actual glucose levels. A customized algorithm is trained and embedded into the wearable CGMs for edge computing. The DuoLoop system shows improved safety in preliminary in vivo test (longer normoglycemia durations, 98.82% vs 92.10%), encouraging its deployment toward precision diabetes care.
Developing scaffolds with appropriate mechanical/structural features as well as tunable bioactivities are indispensable in the field of tissue engineering. This study focused on one such attempt to electrospin the copolymer of L-lactic acid (L-LA) and functional monomer (3(S)- [(benzyloxycarbony)methyl]-1,4-dioxane-2,5-dione, BMD) with small peptide modifications for the purpose of neural tissue engineering. Scanning Electron Microscopy (SEM) micrographs showed fabricated electrospun copolymer as porous and uniform nanofibrous materials with diameter in the range of 800–1000 nm. In addition, the modified scaffolds displayed a lower contact angle than poly(L-lactide) (PLLA) indicating higher hydrophilicity. To further incorporate the bioactive functions, the nanofibers were chemically coupled with small peptide (isoleucine-lysine-valine-alanine-valine, IKVAV). The incorporation of IKVAV onto the electrospun fiber was confirmed by X-ray photoelectron spectroscopy (XPS) and such incorporation did not affect the surface morphology or fiber diameters. To demonstrate the potential of applying the designed scaffolds for nerve regeneration, dorsal root ganglion (DRG) neurons were cultured on the nanofibers to examine the impact on neurite outgrowth of DRGs. The results indicated that the fabricated nanofibrous matrix with small peptide might be a potential candidate for neural tissue engineering.
Fabrication of multifunctional scaffolds with biomimicking physical and biological signals play an important role in enhancing tissue regeneration. Multifunctional features come from composite scaffold with various bioactive molecules. However, simple, biocompatible and controllable hybridization strategy is still lacking. Here, we leverage naturally derived extracellular matrix (ECM) as chemically controllable hydrogel carrier to effectively load functional biomolecules. The use of ECM hydrogel takes advantage of both native functionality of ECM components and tunability of hydrogel in controlling release of loaded molecules. As a proof of concept, porous acellular bone scaffold was selected as the solid pristine scaffold to be composited with BMP-2 and VEGF, which are loaded by spinal cord derived ECM (SC-ECM) hydrogel. Crosslinking degree of SC-ECM hydrogel is tuned by changing genipin concentration, which renders the control over release kinetics of BMP-2 and VEGF. The mechanical strength of scaffold maintained after hybridization and is not significantly decreased in wet condition. In vitro evaluations of scaffolds cocultured with osteoblasts and mesenchymal stem cells (MSCs) demonstrate the biocompatible and bioactive features resulting from the composite scaffolds. Evidenced by alkaline phosphatase test, Immunofluorescence and Real-Time PCR, differentiation of MSCs towards osteoblasts lineage is significantly enhanced by composite scaffolds. Therefore, our strategy in fabricating composite scaffold enabled by biomolecule-loaded ECM hydrogel holds great promise in regenerating diverse tissue types by appropriate combinations of solid pristine scaffolds, ECM, and bioactive molecules.